An Engineered Factor Va Prevents Bleeding Induced by Anticoagulant wt Activated Protein C

OBJECTIVE: An increased risk of bleeding is observed in patients receiving activated protein C (APC), which may be a limiting factor for the application of novel APC therapies. Since APC's therapeutic effects often require its cytoprotective activities on cells but not APC's anticoagulant...

Descripción completa

Detalles Bibliográficos
Autores principales: von Drygalski, Annette, Bhat, Vikas, Gale, Andrew J., Burnier, Laurent, Cramer, Thomas J., Griffin, John H., Mosnier, Laurent O.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2014
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4134195/
https://www.ncbi.nlm.nih.gov/pubmed/25127130
http://dx.doi.org/10.1371/journal.pone.0104304

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4134195/
https://www.ncbi.nlm.nih.gov/pubmed/25127130
http://dx.doi.org/10.1371/journal.pone.0104304

Ejemplares similares